By Joe Makowiecki, Enterprise Solutions Director of Business Development, and Harlan Knapp, Business Development Manager, Cytiva
Viral vectors have been playing an important role in the growing cell and gene therapy market. Seven of the FDA-approved cell and gene therapies utilize or are viral vectors. Now, nearly a quarter of COVID-19 vaccines in development require viral vectors for the spike protein delivery. The FDA predicts that, by 2025, the agency will approve 10 to 20 cell and gene therapy products each year.
However, complex and challenging manufacturing processes may affect the ability to efficiently produce viral vectors on a larger scale. To unlock their full potential, we must understand the existing difficulties in viral vector production and which upstream and downstream processing technologies are now available.
This article reviews your options for viral vector manufacturing, the upstream challenges and downstream considerations in viral vector production, and integrating automation in and selecting a vendor for your viral vector manufacturing line.